Ganoderma lucidum polysaccharide
Based on 1 publication(s) in Google Scholar
Ganoderma Lucidum/Reishi Extract is a Ganoderma lucidum extract. Ganoderma Lucidum/Reishi Extract reduces the expression of c-Myc, BCL-2, BCL-XL, TERT, PDGFB, eIF4G, Survivin, β-catenin, and eIF4E. Ganoderma Lucidum/Reishi Extract downregulates the gene expression of MMP-9. Ganoderma Lucidum/Reishi Extract upregulates the expression of IL8. Ganoderma Lucidum/Reishi Extract is applicable to the research of inflammatory breast cancer. Ganoderma Lucidum is used in the research of various diseases, such as allergy, arthritis, hypertension, neurasthenia, inflammation, and cancer.
For research use only. We do not sell to patients.
- Assay : 41.20%
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) Ganoderma lucidum polysaccharide
More
Biological Activity
Description
IC50 & Target
[1]|
MMP-9 |
IL-8 |
eIF4G |
eIF4E |
Bcl-xL |
Bcl-2 |
In Vitro
Ganoderma Lucidum/Reishi Extract (0.05-1.0 mg/mL; 24-96 h) selectively inhibits viability across multiple cancer cell lines, including SUM-149 IBC cells (with 50% inhibition at 0.25 mg/mL over 96 hours), while causing minimal viability reduction in noncancerous MCF10A mammary epithelial cells[1].
Ganoderma Lucidum/Reishi Extract (0.5 mg/mL; 24 h) induces apoptosis in ~90% of SUM-149 IBC cells after 24-hour treatment with 0.5 mg/mL[1].
Ganoderma Lucidum/Reishi Extract (0.5 mg/mL; 24 h) inhibits invasion of SUM-149 IBC cells by 80% after 24-hour treatment with 0.5 mg/mL[1].
Ganoderma Lucidum/Reishi Extract (0.5 mg/mL; 48 h) disrupts tumor spheroid formation in SUM-149 IBC cells after 48-hour treatment with 0.5 mg/mL[1].
Ganoderma Lucidum/Reishi Extract (0.5 mg/mL; 24 h) reduces MMP-2 and MMP-9 gelatinase activity by ~50% in SUM-149 IBC cells after 24-hour treatment with 0.5 mg/mL[1].
Ganoderma Lucidum/Reishi Extract (0.5 mg/mL; 24 h) reduces expression of key survival, adhesion, and translation-related proteins (including BCL-2, E-cadherin, eIF4G, c-Myc) in SUM-149 IBC cells after 24-hour treatment with 0.5 mg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SUM-149 inflammatory breast cancer (IBC) cells, MCF10A noncancerous mammary epithelial cells, MDA-MB-468 breast cancer cells, MDA-MB-435 breast cancer cells, A-172 glioma cells, MiaPaCa pancreatic cancer cells
-
Concentration:0.5-1.0 mg/mL (24 h incubation for all cell lines); 0.05-1.0 mg/mL (96 h incubation with dosing every 48 h for SUM-149 cells)
-
Incubation Time:24 h (all cell lines); 96 h (SUM-149 cells with dosing every 48 h)
-
Result:Reduced SUM-149 viability by 67% at 0.5 mg/mL and 98% at 1.0 mg/mL after 24 h.
Left MCF10A viability unchanged at 0.5 mg/mL and reduced it by 11% at 1.0 mg/mL after 24 h.
Reduced MDA-MB-468 viability by 31% at 0.5 mg/mL and an additional 45% at 1.0 mg/mL after 24 h.
Reduced MDA-MB-435 viability by 60% at 0.5 mg/mL and an additional 91% at 1.0 mg/mL after 24 h.
Reduced A-172 viability by 31% at 0.5 mg/mL and an additional 49% at 1.0 mg/mL after 24 h.
Reduced MiaPaCa viability by 41% at 0.5 mg/mL with no additional effect at 1.0 mg/mL after 24 h.
Increased SUM-149 viability by 14% at 0.05 mg/mL, reduced viability by 50% at 0.25 mg/mL, 82% at 0.5 mg/mL, and 90% at 1.0 mg/mL after 96 h.
Achieved 50% inhibition of SUM-149 viability at 0.25 mg/mL over 96 h.
-
Cell Line:SUM-149 IBC cells
-
Concentration:0.5 mg/mL
-
Incubation Time:24 h
-
Result:Impaired SUM-149 cell invasion into the Matrigel matrix by 80% compared to controls.
-
Cell Line:SUM-149 IBC cells
-
Concentration:0.5 mg/mL
-
Incubation Time:8 h
-
Result:Downregulated BCL2, CDKN2A, FGFR2, PDGFB, TERT, and MMP9.
Upregulated IL8.
-
Cell Line:SUM-149 IBC cells
-
Concentration:0.5 mg/mL
-
Incubation Time:24 h
-
Result:Reduced protein expression of BCL-2 (1.6-fold), BCL-XL (1.9-fold), survivin (1.3-fold), E-cadherin (1.7-fold), beta-catenin (1.3-fold), c-Myc (2-fold), p120-catenin (3-fold), eIF4G (2.2-fold), and eIF4E (1.3-fold) compared to controls.
Chemical Information
-
Appearance Solid
-
Color Brown to orange
-
SMILES
[Ganoderma lucidum polysaccharide]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
H2O : 4 mg/mL (ultrasonic and warming and heat to 60°C)
Protocols
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Martínez-Montemayor MM, et al. Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer. Nutr Cancer. 2011;63(7):1085-1094. [Content Brief]
[2]. Sliva D, et al. Cellular and physiological effects of Ganoderma lucidum (Reishi). Mini Rev Med Chem. 2004;4(8):873-879. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Ganoderma lucidum polysaccharide
- c-Myc
- Bcl-2 Family
- Eukaryotic Initiation Factor (eIF)
- Survivin
- β-catenin
- MMP
- Interleukin Related
- MCF-7 cells
- Vero cells
- inflammatory breast cancer
- MCF10A mammary epithelial cells
- HL-60 leukemia cells
- U937 leukemia cells
- MT-4 cells
- HeLa cells
- SUM-149 IBC cells
- PC12 neuronal cells
- Inhibitor
- inhibitor
- inhibit